Clinical Trials
15 trialsNCT02073123 2026-05-29
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Lumos Pharma
Phase 1/2 Completed
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03301636 2022-09-27
NLG2107
Lumos Pharma
Phase 2 Terminated
NCT02460367 2022-04-06
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1 Terminated
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT00739609 2020-05-28
D-1MT
Lumos Pharma
Phase 1 Terminated
NCT01792050 2020-05-28
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Lumos Pharma
Phase 2 Completed
NCT01560923 2020-04-03
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01042535 2018-04-11
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01302821 2017-02-23
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Withdrawn
NCT00567931 2014-07-24
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01191216 2014-07-24
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed